Identification of Metabolites of the Novel 5α-Reductase Inhibitor Epristeride and Its Impact on Steroid Detection in Asians compared to Caucasians: A Focus on UGT2B17 Genetic Polymorphism

Code: 252C03BL

In steroid hormone testing, the biological passport indicators of athletes, which serve as longitudinal monitoring parameters, are susceptible to interference from various factors, and 5α-reductase inhibitors represent one such co-founding factor. Given that other 5α-reductase inhibitors, such as finasteride and dutasteride, are already monitored for their potential impact on steroid detection in anti-doping, comprehensive metabolic studies of epristeride are crucial to understand its impact for doping control purposes. Epristeride, a novel non-competitive inhibitor of type II 5α-reductase, has emerged as a potential therapeutic alternative for benign prostatic hyperplasia. This study aims to investigate the metabolic characteristics of Epristeride and elucidate its metabolic pathways in humans, investigating its impact on the steroid indicators of athletes' biological passports, examining the differences in effects among populations with different genotypes, and comparing the variations in effects between the Chinese population and the Caucasian population. Thereby providing a scientific basis for assessing its potential risks to athletes and doping control.